UCL Institute of Neurology


IoN News

A new clinical trial at the LWENC CRF to test a potential disease-modifying agent in Parkinson’s disease – the AIM-PD trial

A new trial that investigates whether a drug called ABX can influence the levels of a crucial enzyme in patients with Parkinson’s disease (PD) has recently started at the Leonard Wolfson Experimental Neurology Centre (LWENC) Clinical Research Facility (CRF), based at the UCL Institute of Neurology, the Royal Free London hospital and the National Hospital for Neurology and Neurosurgery (UCLH).

Publication date: